Moleculin Gains Strong Physician Prescribe Intent for Annamycin in Relapsed/Refractory AML Survey

An independent market landscape assessment positions Moleculin Biotech's Annamycin closer to commercial planning territory, with hematologist-oncologists returning an average likelihood-to-prescribe score of 6 out of 7 for relapsed/refractory acute myeloid leukemia, a signal that will sharpen CMC and manufacturing scale-up conversations if Phase III data supports an NDA filing.

The survey drew responses from academic and community hematologist-oncologists, medical oncologists, and pediatric AML specialists. Respondents cited complete remission rates, MRD-negative responses, transplant-bridging potential, and biomarker-agnostic applicability as the primary clinical drivers. Reduced cardiotoxicity relative to traditional anthracyclines was identified as a meaningful differentiator, with pediatric specialists noting particular relevance given long-term survivorship concerns and the possibility of repeat dosing cycles.

Physicians consistently flagged a structural gap in the R/R AML treatment landscape: targeted therapies have improved outcomes for biomarker-defined subgroups, but patients without actionable mutations, and those progressing after venetoclax-based regimens, remain without reliable salvage options. Durable remission and successful bridge to transplant were the most frequently cited treatment goals, aligning directly with the efficacy profile Annamycin's clinical data has reported to date.

Parallel interviews with hospital administrators and payers reinforced the commercial read. Insurers indicated that Annamycin's efficacy and safety profile, combined with broad patient applicability, could support a defensible value proposition, a finding relevant to market access teams beginning formulary and reimbursement modelling ahead of any potential approval.

For regulatory and CMC leads, the market research itself carries no submission weight, but the breadth of stakeholder alignment, spanning community oncologists, academic centres, paediatric specialists, and payers, suggests that commercial infrastructure planning should run in parallel with ongoing Phase III execution rather than follow it.

The next measurable checkpoint is Phase III efficacy data, which will determine whether the prescribe-intent scores documented here translate into a viable NDA package and the manufacturing readiness requirements that accompany it.

Source: Moleculin Biotech, Inc. via GlobeNewswire, June 5, 2026.